产品
编 号：F743404
分子式：C149H225N39O46
分子量：3298.61
分子式：C149H225N39O46
分子量：3298.61
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 123475-27-4
产品详情
生物活性：
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH).
体内研究：
Beinaglutide (0.6、1.2、2.4 mg/kg；sc；每天 3 次，连续 7 天) 在小鼠中显示出控制血糖、抑制食物摄入和体重减轻的能力。 Beinaglutide (150 μg/kg；sc；每日一次，持续 6 周) 增加脂肪细胞的胰岛素敏感性。Animal Model:Wild-type male C57BL/6 mice and Male Lepob/Lepob (ob/ob) mice (ob/ob-NASH mouse model was induced by GAN diet)
Dosage:0.6, 1.2, 2.4 mg/kg
Administration:S.c.; three times per day for 7 consecutive days
Result:Significantly reduced blood glucose with dosedependence in C57BL/6 and ob/ob mice, dose dependently inhibits food intake and gastric Emptying, and significantly reduced body weight, food intake with dose-dependence.
Animal Model:Eight-week-old male C57BL/6 mice
Dosage:150 μg/kg
Administration:S.c.; daily for 6 weeks
Result:Showed improved glucose tolerance and insulin sensitivity, decreased adipose tissue weight and adipocyte size and potentiated insulin sensitivity of adipocytes.
体外研究：
Beinaglutide (100 nM；48 小时) 增加脂肪细胞中 Akt 磷酸化的表达，这些脂肪细胞被增强的胰岛素刺激。
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH).
体内研究：
Beinaglutide (0.6、1.2、2.4 mg/kg；sc；每天 3 次，连续 7 天) 在小鼠中显示出控制血糖、抑制食物摄入和体重减轻的能力。 Beinaglutide (150 μg/kg；sc；每日一次，持续 6 周) 增加脂肪细胞的胰岛素敏感性。Animal Model:Wild-type male C57BL/6 mice and Male Lepob/Lepob (ob/ob) mice (ob/ob-NASH mouse model was induced by GAN diet)
Dosage:0.6, 1.2, 2.4 mg/kg
Administration:S.c.; three times per day for 7 consecutive days
Result:Significantly reduced blood glucose with dosedependence in C57BL/6 and ob/ob mice, dose dependently inhibits food intake and gastric Emptying, and significantly reduced body weight, food intake with dose-dependence.
Animal Model:Eight-week-old male C57BL/6 mice
Dosage:150 μg/kg
Administration:S.c.; daily for 6 weeks
Result:Showed improved glucose tolerance and insulin sensitivity, decreased adipose tissue weight and adipocyte size and potentiated insulin sensitivity of adipocytes.
体外研究：
Beinaglutide (100 nM；48 小时) 增加脂肪细胞中 Akt 磷酸化的表达，这些脂肪细胞被增强的胰岛素刺激。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备